Mozobil

Plerixafor in combination with G-CSF to enhance mobilisation of haematopoietic stem cells to peripheral blood for collection and autologous transfusion in patients with lymphoma or multiple myeloma.

Plerixafor reversibly blocks the chemokine receptor CXCR4 to prevent binding of its ligand CXCL12 (stromal cell-derived factor-1α).

The drug is injected after four days of treatment with granulocyte-colony stimulating factor (G-CSF), 6-11 hours before initiation of apheresis. Following administration, both haematopoietic progenitor cells and mature leukocytes appear in the systemic circulation.

View Mozobil drug record

Further information: Genzyme

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Calcium and Vitamin D Supplements for Osteoporosis

Calcium and Vitamin D Supplements for Osteoporosis

Formulations, doses and costs of osteoporosis supplements.

Asthma and COPD Preparations and Compatible Devices

Asthma and COPD Preparations and Compatible Devices

Available presentations of bronchodilators and anti-inflammatories.

Topical Steroids, Comparison of Potencies and Formulations

Topical Steroids, Comparison of Potencies and Formulations

Strengths and formulations of topical steroids.

Topical Steroids, Potential Skin Sensitisers as Ingredients

Topical Steroids, Potential Skin Sensitisers as Ingredients

Potential sensitising agents in topical steroids.